Clinical Trend of the Week (October 7-13): Verzenio
US Food and Drug Administration (FDA) approval of a drug designed to treat a serious condition has once again resulted in this week's top search term. Abemaciclib (Verzenio, Eli Lilly) has become the third FDA-approved cyclin-dependent kinase (CDK) 4/6 inhibitor designed for use in breast cancer, joining palbociclib (Ibrance, Pfizer) and ribociclib (Kisqali, Novartis). What sets abemaciclib apart is that it can be administered as a stand-alone treatment to patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer who were previously treated with endocrine therapy and chemotherapy. The popularity of searches for this term reflects the severity of the condition, as breast cancer remains the most frequently diagnosed life-threatening cancer in women and the leading cause of cancer death among women worldwide.
For more information on breast cancer, read here.
Medscape © 2017
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ryan Syrek. Clinical Trends for October 2017 - Medscape - Oct 20, 2017.